E10.35 Category · further specificity required Type 1 diabetes mellitus with proliferative diabetic retinopathy
ICD-10-CM E10.35 identifies “Type 1 diabetes mellitus with proliferative diabetic retinopathy” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 4: Endocrine, nutritional and metabolic diseases
Code-level instructions
Seventh character1
One of the following 7th characters is to be assigned to codes in subcategory E10.35 to designate laterality of the disease:
1 — right eye
2 — left eye
3 — bilateral
9 — unspecified eye
Inherited instructions
Chapters 4 · Endocrine, nutritional and metabolic diseases (E00-E89)
Excludes 11
transitory endocrine and metabolic disorders specific to newborn (P70-P74)
Note1
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
E10 · Type 1 diabetes mellitus
Includes6
- brittle diabetes (mellitus)
- diabetes (mellitus) due to autoimmune process
- diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction
- idiopathic diabetes (mellitus)
- juvenile onset diabetes (mellitus)
- ketosis-prone diabetes (mellitus)
Excludes 19
- diabetes mellitus due to underlying condition (E08.-)
- drug or chemical induced diabetes mellitus (E09.-)
- gestational diabetes (O24.4-)
- hyperglycemia NOS (R73.9)
- neonatal diabetes mellitus (P70.2)
- postpancreatectomy diabetes mellitus (E13.-)
- postprocedural diabetes mellitus (E13.-)
- secondary diabetes mellitus NEC (E13.-)
- type 2 diabetes mellitus (E11.-)
More specific codes
E10.351Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edemaCategory · further specificity requiredE10.352Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the maculaCategory · further specificity requiredE10.353Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the maculaCategory · further specificity requiredE10.354Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachmentCategory · further specificity requiredE10.355Type 1 diabetes mellitus with stable proliferative diabetic retinopathyCategory · further specificity requiredE10.359Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edemaCategory · further specificity requiredOfficial index references
History
Code history
Latest recorded change · FY2017
Effective from
- Code-level rules changed
Type 1 diabetes mellitus with proliferative diabetic retinopathy
Category — select a more specific code
CDC/NCHS · FY2017All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | Code-level rules changed |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.